Group 1 - The animal vaccine sector experienced a decline of 0.72% as of the market close on August 22, ranking among the top declines in concept sectors [1] - Within the animal vaccine sector, companies such as Shenlian Biological, Weilan Biological, and Xianfeng Holdings saw significant declines, while Kexing Pharmaceutical, Haizheng Pharmaceutical, and Guoyao Modern recorded increases of 2.06%, 0.44%, and 0.09% respectively [1] - The overall market saw a net outflow of 0.68 billion yuan from the animal vaccine sector, with 11 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The top net outflow in the animal vaccine sector was from Kanghua Biological, with a net outflow of 30.50 million yuan, followed by Shenlian Biological, Dabeinong, and Jinhai Biological with outflows of 27.38 million yuan, 24.27 million yuan, and 23.53 million yuan respectively [2] - Conversely, the stocks with the highest net inflows included Haizheng Pharmaceutical, Kexing Pharmaceutical, and Luoniushan, with net inflows of 27.34 million yuan, 16.70 million yuan, and 10.38 million yuan respectively [3] - The trading activity in the animal vaccine sector showed that Kanghua Biological had a turnover rate of 3.52% and a decline of 1.70%, while Kexing Pharmaceutical had a turnover rate of 3.12% and an increase of 2.06% [3]

Market Overview - The animal health sector experienced a decline of 0.76% on August 22, with Yongshun Biological leading the drop [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Individual Stock Performance - Yongshun Biological (code: 839729) closed at 11.18, down 4.36% with a trading volume of 91,600 shares and a turnover of 102 million yuan [1] - Dayu Biological (code: 871970) closed at 10.13, down 2.78% with a trading volume of 32,700 shares and a turnover of 33.49 million yuan [1] - Shunlian Biological (code: 688098) closed at 12.74, down 2.00% with a trading volume of 317,600 shares and a turnover of 412 million yuan [1] - Other notable declines include Xianfeng Holdings (code: 002141) down 1.79% and Jinhai Biological (code: 002688) down 1.36% [1] Capital Flow Analysis - The animal health sector saw a net outflow of 74.19 million yuan from institutional investors, while retail investors had a net inflow of 91.60 million yuan [1] - Key stocks with significant capital flow include: - Huisheng Biological (code: 300871) with a net outflow of 9.62 million yuan from institutional investors [2] - Kexin Biological (code: 688526) with a net inflow of 7.28 million yuan from institutional investors [2] - ST Lvkang (code: 002868) had a net outflow of 3.99 million yuan from institutional investors but a net inflow of 3.77 million yuan from retail investors [2]

证券之星消息，8月20日动物保健板块较上一交易日上涨0.27%，贤丰控股领涨。当日上证指数报收于 3766.21，上涨1.04%。深证成指报收于11926.74，上涨0.89%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002141 | 后丰控股 | 4.66 | 9.91% | 128.85万 | | 5.73亿 | | 688526 | 科前生物 | 17.75 | 1.02% | 3.69万 | | 6491.03万 | | 838275 | 驱动力 | 10.24 | 0.69% | 2.68万 | | 2725.11万 | | 603566 | 普莱柯 | 15.30 | 0.39% | 5.28万 | | 8055.89万 | | 600195 | 中牧股份 | 7.70 | 0.39% | 10.24万 | | 7851.28万 | | 871970 | 大禹生物 | 10.27 | 0.39% | 3.79万 | | 3888. ...

8月19日，海利生物今日收盘7.34元，上涨1.66%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到25.90倍，总市值48.13亿元。 上海海利生物技术股份有限公司的主营业务是体外诊断试剂（IVD）业务板块和口腔组织修复与再生材 料业务板块。公司的主要产品是兽用生物制品、医疗器械。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均59.49倍，行业中值40.19倍，海利生物排 名第52位。 股东方面，截至2025年3月31日，海利生物股东户数31505户，较上次减少1319户，户均持股市值35.28 万元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13海利生物25.9028.113.0548.13亿行业平均 59.4955.005.10121.17亿行业中值40.1939.642.9559.18亿1九安医疗11.6511.780.92196.54亿2英科医疗 15.3616.561.37242.73亿3新华医疗16.2915.101.33104.41亿4山东药玻16.3516.401.88154.62亿5奥美医疗 17.0016.661.7561 ...

证券之星消息，8月18日动物保健板块较上一交易日上涨2.2%，申联生物领涨。当日上证指数报收于 3728.03，上涨0.85%。深证成指报收于11835.57，上涨1.73%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688098 | 申联生物 | 12.83 | 20.02% | 13.27万 | 1.69 Z | | 300871 | 回盛生物 | 24.26 | 7.87% | 30.00万 | 7.20亿 | | 838275 | 驱动力 | 10.02 | 6.60% | 4.35万 | 4273.62万 | | 002141 | 贤丰控股 | 3.91 | 4.27% | 1 85.59万 | 3.38亿 | | 839729 | 永顺生物 | 9.95 | 3.65% | 3.11万 | 3066.40万 | | 871970 | 大禹生物 | 9.98 | 3.42% | 2.96万 | 2928.24万 | | 300119 | 瑞普生物 | ...

通过天眼查大数据分析，上海海利生物技术股份有限公司共对外投资了8家企业，参与招投标项目92 次，知识产权方面有商标信息5条，专利信息49条，此外企业还拥有行政许可272个。 海利生物最新一期业绩显示，截至2025一季报，公司营业总收入6179.30万元、同比减少12.11%，归属 净利润1090.17万元，同比增长393.11%，扣非净利润919.93万元，同比增长273.88%，流动比率8.226、 速动比率7.525、资产负债率5.81%。 天眼查商业履历信息显示，上海海利生物技术股份有限公司，成立于1981年，位于上海市，是一家以从 事科技推广和应用服务业为主的企业。企业注册资本65566.22万人民币，实缴资本21000万人民币。公 司法定代表人为张海明。 金融界消息 截至2025年8月15日收盘，海利生物（603718）报收于7.19元，上涨0.84%，换手率2.17%， 成交量14.08万手，成交金额1.01亿元。 资金流向方面，今日主力资金净流出1582.53万元，占比成交额15.71%。其中，超大单净流出2241.58万 元、占成交额22.26%，大单净流入659.06万元、占成交额6.54% ...

8月14日，海利生物今日收盘7.13元，下跌1.93%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到25.16倍，总市值46.75亿元。 上海海利生物技术股份有限公司的主营业务是体外诊断试剂（IVD）业务板块和口腔组织修复与再生材 料业务板块。公司的主要产品是兽用生物制品、医疗器械。 最新一期业绩显示，2025年一季报，公司实现营业收入6179.30万元，同比-12.11%；净利润1090.17万 元，同比393.11%，销售毛利率75.96%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13海利生物25.1627.312.9646.75亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿5振德医疗 17.0416.061.0861.87亿6奥美医疗17.0716.731.7561.68亿7九强生物17.6516.412.16 ...

证券之星消息，8月13日动物保健板块较上一交易日下跌0.53%，大禹生物领跌。当日上证指数报收于 3683.46，上涨0.48%。深证成指报收于11551.36，上涨1.76%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603718 海利生物 | | = 228.37万 | 1.61% | -99.03万 | -0.70% | -129.35万 | -0.91% | | 688526 科前生物 | | 132.14万 | 2.41% | 301.36万 | 5.49% | -433.50万 | -7.90% | | 002868 | *ST绿康 | -31.21万 | -0.66% | 8.74万 | 0.18% | 22.47万 | 0.48% | | 688098 | 申联生物 | -111.83万 | -0.67% | 291.98万 | 1.74% | -180.14万 | ...

8月12日，海利生物今日收盘7.31元，下跌3.94%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到25.80倍，总市值47.93亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入6179.30万元，同比-12.11%；净利润1090.17万 元，同比393.11%，销售毛利率75.96%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13海利生物25.8028.003.0447.93亿行业平均 57.5153.344.97120.28亿行业中值41.2539.962.9558.75亿1九安医疗11.2611.380.89189.95亿2英科医疗 15.0516.231.34237.81亿3山东药玻16.1716.221.86152.96亿4新华医疗16.9415.701.38108.60亿5振德医疗 17.3716.371.1063.04亿6奥美医疗17.5417.191.8063.39亿7九强生物17.9216.672.2088.77亿8康德莱 18.7518.761.5540.40亿9维力医疗18.7920.082.3644.05亿10奥泰生物19.3120.361. ...

来源：金融界 主力资金净流出居前的分别为安杰思（1536.17万元）、科华生物（1457.06万元）、海利生物（1440.72 万元）、华大基因（1419.47万元）、福瑞股份（1329.15万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300760迈瑞医疗230.5-0.098724.29万元 6.07%2300753爱朋医疗34.261.935531.45万元7.53%3300314戴维医疗15.2510.035504.85万元 11.77%4603658安图生物42.343.394457.47万元15.08%5688273麦澜德44.759.234025.59万元9.14%6002432 九安医疗40.121.192866.50万元6.27%7600587新华医疗18.144.432682.44万元3.88%8300453三鑫医疗 9.413.982472.80万元10.27%9688271联影医疗130.68-0.021943.47万元5.25%10603309维力医疗 14.92.831756.01万元10.29% 8月11日，医疗器械行业上涨1.65%，今日主力资金流出4.97亿元，成分 ...